BioCentury | Dec 21, 2017
Translation in Brief

Replacing the replacements

...Duke University licensed Opara’s porcine β cell encapsulation technology in 1998 to MicroIslet Inc., now Islet Sciences Inc....
...encapsulated ovarian constructs in rats corrects abnormalities of ovarian failure.” Nature Communications (2017) Allison Johnson, Staff Writer Islet Sciences Inc. MicroIslet...
BioCentury | May 18, 2015
Clinical News

Remogliflozin etabonate: Additional Phase IIb data

...from Kissei (see BioCentury, Jan. 10, 2011). BHV Pharma Inc. , Research Triangle Park, N.C. Islet Sciences Inc....
BioCentury | Apr 13, 2015
Company News

BHV Pharma, Islet Sciences deal

...Nagano, Japan) (see BioCentury, Jan. 10, 2011). BHV Pharma Inc. , Research Triangle Park, N.C. Islet Sciences Inc....
BioCentury | Nov 17, 2014
Company News

BHV Pharma, Libbs deal

...BHV will receive a percentage of either net sales or net profit in Libbs' territories. Islet Sciences Inc....
BioCentury | Jun 2, 2014
Company News

Islet Sciences management update

Islet Sciences Inc. (OTCBB:ISLT), New York, N.Y. Business: Endocrine/Metabolic, Transplant Hired: Steven Delmar as CFO, formerly director of business operations at Computer Sciences Corp. WIR Staff Transplant...
BioCentury | Apr 21, 2014
Clinical News

Remogliflozin etabonate: Phase IIb data

...BHV and Islet Sciences Inc. (OTCBB:ISLT, New York, N.Y.) reported data from a pair of double-blind, dose-ranging, placebo...
...presented at the American Diabetes Association meeting in San Francisco in June. Additionally, BHV and Islet Sciences...
...dosing limiting the undesirable effects of nighttime inhibition of SGLT2. As a result, BHV and Islet Sciences...
BioCentury | Apr 16, 2014
Clinical News

BHV, Islet report Phase IIb data for SGLT2 inhibitor

...BHV Pharma Inc. (Research Triangle Park, N.C.) and Islet Sciences Inc. (OTCBB:ISLT) reported data on Wednesday from a...
...both trials will be presented at the American Diabetes Association meeting in June. BHV and Islet Sciences...
...remogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, from Kissei Pharmaceutical Co. Ltd. (Tokyo:4547). Last month, Islet Sciences...
BioCentury | Mar 17, 2014
Company News

BHV Pharma, Islet Sciences deal

...BHV shareholders 30 million shares of Islet Sciences common stock, valued at $12 million based on Islet Sciences'...
...million in additional shares to BHV shareholders based on milestones related to BHV's remogliflozin etabonate. Islet Sciences...
...Type I diabetes and insulin-dependent Type II diabetes. Neither company has reported revenue. Last November, Islet Sciences...
BioCentury | Nov 11, 2013
Company News

Islet Sciences management update

Islet Sciences Inc. (OTCBB:ISLT), New York, N.Y. Business: Endocrine/Metabolic, Transplant Hired: James Green as CEO, formerly chairman and CEO of BHV Pharma Inc. ; and William Wilkison as COO, formerly a director and CSO of...
BioCentury | Jul 22, 2013
Company News

Islet Sciences management update

Islet Sciences Inc. (OTCBB:ISLT), New York, N.Y. Business: Endocrine/Metabolic, Transplant Hired: Michael Earley as CEO and chairman, formerly CEO and chairman of Metropolitan Health Networks Inc.; he succeeds John Steel, who remains a director WIR...
Items per page:
1 - 10 of 15
BioCentury | Dec 21, 2017
Translation in Brief

Replacing the replacements

...Duke University licensed Opara’s porcine β cell encapsulation technology in 1998 to MicroIslet Inc., now Islet Sciences Inc....
...encapsulated ovarian constructs in rats corrects abnormalities of ovarian failure.” Nature Communications (2017) Allison Johnson, Staff Writer Islet Sciences Inc. MicroIslet...
BioCentury | May 18, 2015
Clinical News

Remogliflozin etabonate: Additional Phase IIb data

...from Kissei (see BioCentury, Jan. 10, 2011). BHV Pharma Inc. , Research Triangle Park, N.C. Islet Sciences Inc....
BioCentury | Apr 13, 2015
Company News

BHV Pharma, Islet Sciences deal

...Nagano, Japan) (see BioCentury, Jan. 10, 2011). BHV Pharma Inc. , Research Triangle Park, N.C. Islet Sciences Inc....
BioCentury | Nov 17, 2014
Company News

BHV Pharma, Libbs deal

...BHV will receive a percentage of either net sales or net profit in Libbs' territories. Islet Sciences Inc....
BioCentury | Jun 2, 2014
Company News

Islet Sciences management update

Islet Sciences Inc. (OTCBB:ISLT), New York, N.Y. Business: Endocrine/Metabolic, Transplant Hired: Steven Delmar as CFO, formerly director of business operations at Computer Sciences Corp. WIR Staff Transplant...
BioCentury | Apr 21, 2014
Clinical News

Remogliflozin etabonate: Phase IIb data

...BHV and Islet Sciences Inc. (OTCBB:ISLT, New York, N.Y.) reported data from a pair of double-blind, dose-ranging, placebo...
...presented at the American Diabetes Association meeting in San Francisco in June. Additionally, BHV and Islet Sciences...
...dosing limiting the undesirable effects of nighttime inhibition of SGLT2. As a result, BHV and Islet Sciences...
BioCentury | Apr 16, 2014
Clinical News

BHV, Islet report Phase IIb data for SGLT2 inhibitor

...BHV Pharma Inc. (Research Triangle Park, N.C.) and Islet Sciences Inc. (OTCBB:ISLT) reported data on Wednesday from a...
...both trials will be presented at the American Diabetes Association meeting in June. BHV and Islet Sciences...
...remogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, from Kissei Pharmaceutical Co. Ltd. (Tokyo:4547). Last month, Islet Sciences...
BioCentury | Mar 17, 2014
Company News

BHV Pharma, Islet Sciences deal

...BHV shareholders 30 million shares of Islet Sciences common stock, valued at $12 million based on Islet Sciences'...
...million in additional shares to BHV shareholders based on milestones related to BHV's remogliflozin etabonate. Islet Sciences...
...Type I diabetes and insulin-dependent Type II diabetes. Neither company has reported revenue. Last November, Islet Sciences...
BioCentury | Nov 11, 2013
Company News

Islet Sciences management update

Islet Sciences Inc. (OTCBB:ISLT), New York, N.Y. Business: Endocrine/Metabolic, Transplant Hired: James Green as CEO, formerly chairman and CEO of BHV Pharma Inc. ; and William Wilkison as COO, formerly a director and CSO of...
BioCentury | Jul 22, 2013
Company News

Islet Sciences management update

Islet Sciences Inc. (OTCBB:ISLT), New York, N.Y. Business: Endocrine/Metabolic, Transplant Hired: Michael Earley as CEO and chairman, formerly CEO and chairman of Metropolitan Health Networks Inc.; he succeeds John Steel, who remains a director WIR...
Items per page:
1 - 10 of 15